998 results on '"Pierga, Jean-Yves"'
Search Results
2. Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib
3. Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis
4. Concomitant medication, comorbidity and survival in patients with breast cancer
5. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy
6. Prevalence and survival implications of malnutrition and sarcopenia in metastatic breast cancer: A longitudinal analysis
7. Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
8. Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience
9. Evolution of synchronous female bilateral breast cancers and response to treatment
10. Clinical outcomes of curative-intent multimodal management of chemorefractory nonmetastatic inflammatory breast cancer
11. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
12. Diagnostic et prise en charge de la pneumopathie interstitielle diffuse induite par les anticorps conjugués dans le cancer du sein : avis d’expert
13. Microsatellite instability detection in breast cancer using drop-off droplet digital PCR
14. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
15. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS
16. TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.
17. Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
18. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
19. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer
20. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
21. Deformation under flow and morphological recovery of cancer cells.
22. Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic
23. Histoire et innovation : chimiothérapie néoadjuvante des cancers du sein
24. Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons
25. Le Collège national des enseignants de cancérologie (CNEC) : missions, organisation et projets
26. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
27. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy
28. Cancer during pregnancy: Factors associated with termination of pregnancy and perinatal outcomes
29. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
30. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
31. A Question Prompt List for Advanced Cancer Patients Promoting Advance Care Planning: A French Randomized Trial
32. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
33. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
34. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
35. COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)
36. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
37. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns
38. Cost effectiveness of CTC guided chemo or endocrine therapy in metastatic breast cancer. Results from a randomized controlled multicenter trial
39. Tolerance of concurrent adjuvant radiotherapy and pembrolizumab for triple negative breast cancer: real life experience
40. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
41. A DNA methylation-based liquid biopsy for triple-negative breast cancer
42. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
43. Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
44. Chimiothérapie et femme jeune dans le cancer du sein : quelle prise en charge ?
45. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)
46. A single droplet digital PCR for ESR1 activating mutations detection in plasma
47. Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
48. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
49. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies
50. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.